Delving into the Latest Updates on LASSBio-1018 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LASSBio1018

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

InflammationPain

Originator Organization

Universidade Federal De Alagoas

Active Organization-

Inactive Organization

Universidade Federal De Alagoas

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Author: Barbosa, Maria Leticia de Castro ; Bispo, Walfrido Jr. ; Dias, Thays de Lima Matos Freire ; Alexandre-Moreira, Magna Suzana ; Lima, Lidia Moreira ; Augusto, Cristina Villarinho ; Melo, Gabriela Muniz de Albuquerque ; Barreiro, Eliezer J. ; Cupertino da Silva, Yolanda Karla ; Cavalcanti de Queiroz, Aline

In this paper, we report the synthesis and pharmacological evaluation of pyrazine N-acylhydrazone (NAH) derivatives (2a-s) designed as novel analgesic and anti-inflammatory drug candidates. This series was planned by molecular simplification of prototype 1 (LASSBio-1018), previously described as a non-selective cyclooxygenase inhibitor. Derivatives 2a-s were evaluated in several animal models of pain and inflammation, standing-out compound 2o (2-N'-[(E)-(3,4,5-trimethoxyphenyl) methylidene]-2-pyrazinecarbohydrazide; LASSBio-1181), that was also active in a murine model of chronic inflammation (i.e., adjuvant-induced arthritis test in rats) and can be considered a new analgesic and anti-inflammatory lead for drug development.

100 Deals associated with LASSBio-1018

Login to view more data